Altimmune, Inc. (NASDAQ:ALT) Expected to Post Quarterly Sales of $150,000.00
Wall Street brokerages forecast that Altimmune, Inc. (NASDAQ:ALT) will post sales of $150,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for…
From the Equity Insider archive. This article dates from Dec 21, 2021 and is preserved as first published.
Wall Street brokerages forecast that Altimmune, Inc. (NASDAQ:ALT) will post sales of $150,000.00 for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Altimmune’s earnings, with the highest sales estimate coming in at $200,000.00 and the lowest estimate coming in at $100,000.00. Altimmune posted sales of $2.31 million in the same quarter last year, which suggests a negative year-over-year growth rate of 93.5%. The business is scheduled to issue its next quarterly earnings results on Thursday, February 24th.
According to Zacks, analysts expect that Altimmune will report full year sales of $1.24 million for the current year, with estimates ranging from $1.10 million to $1.30 million. For the next year, analysts anticipate that the company will post sales of $7.01 million, with estimates ranging from $440,000.00 to $20.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Altimmune.
Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Monday, November 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.45). The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.11 million. Altimmune had a negative net margin of 2,431.80% and a negative return on equity of 32.83%. During the same quarter in the prior year, the company posted ($0.54) earnings per share.
Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Monday, November 8th.
A number of equities research analysts recently commented on ALT shares. JMP Securities restated a “buy” rating and set a $31.00 price target on shares of Altimmune in a research report on Tuesday, September 28th. Zacks Investment Research lowered Altimmune from a “hold” rating to a “sell” rating in a research report on Monday, November 15th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Altimmune in a research note on Monday, August 30th. B. Riley increased their price target on Altimmune from $21.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, September 7th. Finally, Piper Sandler raised their price objective on Altimmune from $16.00 to $34.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 8th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $28.50.
Several hedge funds and other institutional investors have recently made changes to their positions in ALT. Ameritas Investment Partners Inc. bought a new position in shares of Altimmune in the 2nd quarter valued at about $25,000. Legal & General Group Plc bought a new position in Altimmune during the second quarter worth about $26,000. Royal Bank of Canada grew its holdings in Altimmune by 2,032.1% during the second quarter. Royal Bank of Canada now owns 3,987 shares of the company’s stock worth $39,000 after purchasing an additional 3,800 shares during the period. Metropolitan Life Insurance Co NY bought a new position in Altimmune during the second quarter worth about $97,000. Finally, Argent Trust Co bought a new position in Altimmune during the second quarter worth about $99,000. Institutional investors own 76.57% of the company’s stock.
NASDAQ ALT opened at $9.55 on Tuesday. The firm has a market cap of $379.51 million, a PE ratio of -4.87 and a beta of 1.47. Altimmune has a one year low of $8.10 and a one year high of $24.61. The stock’s 50 day simple moving average is $10.71 and its 200 day simple moving average is $12.01.
About Altimmune
Altimmune, Inc is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is developing pemvidutide (ALT-801), a novel, GLP-1/glucagon dual agonist for the treatment of obesity and non-alcoholic steatohepatitis (NASH), and HepTcell(TM), an immunotherapeutic candidate for patients chronically infected with the hepatitis B virus (HBV).
